Germany's Merck posts flat 3rd-qtr sales and earnings decline

9 November 2017

The shares of German life sciences group Merck KGaA (MRK: DE) rose 1.2% to 93.48 euros in early trading, when it released third-quarter 2017 financial results.

Group sales increased in the third quarter by 0.1% to 3.7 billion euros ($4.28 billion), thus maintaining the year-earlier level. Sales grew organically by 4.2% thanks to the Healthcare and Life Science business sectors. However, this was offset by negative foreign exchange effects amounting to –3.7%, which stemmed mainly from the weaker US dollar against the euro. Portfolio changes caused sales to decline by –0.4%. Geographically, all regions contributed to the organic sales growth of the Group.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK